Please login to the form below

Not currently logged in
Email:
Password:

PI3K

This page shows the latest PI3K news and features for those working in and with pharma, biotech and healthcare.

Chi-Med cues up two more regulatory filings in cancer

Chi-Med cues up two more regulatory filings in cancer

Following after its first three drugs are potential first-in-class selective Syk inhibitor HMPL-523, in phase 1 testing for non-Hodgkin’s lymphoma, and a PI3K delta inhibitor

Latest news

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    development and commercialisation. 45. Infinity Pharmaceuticals/ Verastem. Duvelisib, oral inhibitor of PI3K‐delta and PI3K‐gamma for haematological cancers (p3).

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    970. Infinity / AbbVie. Licence and collaboration. IPI-145 an oral PI3K-delta, gamma inhibitor in Phase III for chronic lymphocytic leukaemia .

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics